Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,846 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,846 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 46 | Chinese PLA General HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06171854 | caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.(ABACO) | unknown | Phase 2 | 33 | University of Campania Luigi VanvitelliOTHER | 1 | Jan 2, 2024 |
| NCT05432934 | Transversus Abdominis Plane Blocks With and Without Dexamethasone(TAP-DEX) | unknown | Phase 1 / Phase 2 | 60 | University of SaskatchewanOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05578287 | RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer(DETECT) | unknown | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT03729687 | Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in High-risk Rectal Cancer(LARCT-US) | unknown | Phase 2 | 280 | Uppsala UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06134765 | Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer | unknown | Phase 2 | 89 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05839470 | Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 15, 2023 | clinicaltrials |
| NCT04034459 | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC(AIO-KRK-0116) | unknown | Phase 2 | 109 | Ludwig-Maximilians - University of MunichOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04310176 | Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer(REVOLUTION) | unknown | Phase 2 | 200 | National Cancer Institute, NaplesOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT00294827 | Liver Transplantation and Metastatic Colo-rectal Cancer. | unknown | Phase 2 | 25 | Oslo University HospitalOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06118047 | Crisaborole Ointment for Skin Toxicity Induced by Cetuximab(COSTIC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06120127 | Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence(IMPROVE) | unknown | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04753203 | Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients(ALCAP) | unknown | Phase 1 / Phase 2 | 65 | Korean Cancer Study GroupOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT05785325 | RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06089330 | A Study of JMT101 in Patients With Metastatic Colorectal Cancer | unknown | Phase 2 | 102 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Oct 18, 2023 | clinicaltrials |
| NCT03638297 | PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer(PCOX) | unknown | Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06060704 | Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | unknown | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT05307198 | Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC(RAIC) | unknown | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04033107 | High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors | unknown | Phase 2 | 30 | Zhongnan HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04259944 | Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | unknown | Phase 2 | 140 | IFOM ETS - The AIRC Institute of Molecular OncologyOTHER | 2 | Sep 28, 2023 | clinicaltrials |
| NCT06018714 | Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study | unknown | Phase 2 | 64 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05555901 | The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer | unknown | Phase 2 | 116 | Fudan UniversityOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06017141 | Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study | unknown | Phase 2 | 80 | University of Kansas Medical CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06010888 | Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC | unknown | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05957016 | Neoadjuvant CIETAI With Concurrent Chemoradiotherapy in Local Advanced Rectal Cancer | unknown | Phase 2 | 90 | Third Military Medical UniversityOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT06003998 | Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab(INTERACT-II) | unknown | Phase 2 | 85 | Catharina Ziekenhuis EindhovenOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT04984369 | The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment | unknown | Phase 2 | 50 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04659382 | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer(SIRTCI) | unknown | Phase 2 | 52 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04798612 | Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression(IPOS) | unknown | Phase 2 | 68 | Zealand University HospitalOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05127759 | The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation | unknown | Phase 2 | 25 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05842525 | Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 2 | 42 | Hunan Cancer HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05911789 | Online Adaptive Radiation Therapy for Rectal Cancer | unknown | Phase 1 / Phase 2 | 15 | Peking Union Medical College HospitalOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05970302 | XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC | unknown | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970705 | Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC | unknown | Phase 2 | 101 | Fudan UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05871333 | Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients | unknown | Phase 2 | 80 | Ain Shams UniversityOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT04653480 | Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC | unknown | Phase 2 | 61 | Zhejiang UniversityOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT02560298 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer(InterAACT) | unknown | Phase 2 | 91 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913570 | Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer(MSI-H/dMMR) | unknown | Phase 2 | 22 | LiuYingOTHER_GOV | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04189055 | Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.(CETIDYL) | unknown | Phase 2 | 72 | Hôpital Franco-Britannique-Fondation Cognacq-JayOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03073694 | Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis | unknown | Phase 2 | 100 | University of Kansas Medical CenterOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05160896 | SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer | unknown | Phase 2 | 90 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05894837 | Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT03831698 | Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) | unknown | Phase 2 | 21 | University of Kansas Medical CenterOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT04083365 | Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer(PANDORA) | unknown | Phase 2 | 100 | AUSL Romagna RiminiOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05233332 | Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)(mCRC) | unknown | Phase 2 | 186 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05799820 | QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 25, 2023 | clinicaltrials |
| NCT05868317 | Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer | unknown | Phase 2 | 70 | Salah Azaïz Cancer InstituteOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05382741 | Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial(VIVA) | unknown | Phase 2 | 182 | Ospedale Policlinico San MartinoOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05858567 | Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma(RECMULRA-TNT) | unknown | Phase 2 | 30 | Sir Run Run Shaw HospitalOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05420584 | Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer(NECI) | unknown | Phase 2 | 83 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | May 11, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jan 8, 2024source: clinicaltrials